Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Nirmal Vivek Raut"'
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 4, Iss 1, Pp 184-185 (2021)
Externí odkaz:
https://doaj.org/article/4bfffc94cea341019e8856f25612be37
Autor:
Nirmal Vivek Raut
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 2, Iss 1, Pp 126-127 (2019)
Externí odkaz:
https://doaj.org/article/2b3c1d865be04b5a9f04d25e5d724be8
Publikováno v:
Indian Journal of Medical and Paediatric Oncology. 42:204-207
Treatment of nonsmall cell lung cancer (NSCLC) carrying an epidermal growth factor receptor (EGFR) mutation depends on EGFR tyrosine kinase inhibitors (TKIs). However, all patients treated with EGFR TKI eventually develop progressive disease. Approxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af2fb196567d2c73df341c04b4363b54
https://doi.org/10.1055/s-0041-1731851
https://doi.org/10.1055/s-0041-1731851
Publikováno v:
Indian Journal of Medical and Paediatric Oncology. 41:543-546
In order to overcome the polysorbate induced hypersensitivity reactions with chemotherapy drugs, novel drug-delivery mechanisms have been developed in the last decade. D-alpha-tocopheryl polyethylene glycol succinate (TPGS) is formed by esterificatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ba90281bd2f529f6427c5c5aa487527
https://doi.org/10.4103/ijmpo.ijmpo_214_19
https://doi.org/10.4103/ijmpo.ijmpo_214_19
Autor:
Nirmal Vivek Raut, Atul Bharde, Aland Gourishankar, Sreeja Jayant, Meghana Garbhe, Sayali Gosavi, Apoorva Janorkar, Alain D'Souza, Aravindan Vasudevan, Jayant Khandare
Publikováno v:
Journal of Clinical Oncology. 40:e15021-e15021
e15021 Background: To analyze the role of Circulating tumor cells (CTC) as a confirmatory personalized biomarker for monitoring the disease progression, disease burden, and minimal residual disease in epithelial origin cancers. Methods: In this retro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6194e69fba062a080b3312423bc2a4ac
https://doi.org/10.1200/jco.2022.40.16_suppl.e15021
https://doi.org/10.1200/jco.2022.40.16_suppl.e15021
Autor:
Gowhar Shafi, Shivamurthy P.M., Anand Ulle, Krithika Srinivasan, Aravindan Vasudevan, Vikas Jadhav, Dr Sujit Joshi, Nirmal Vivek Raut, Jayant Khandare, Mohan Uttarwar, Kenneth Joel Bloom
Publikováno v:
Journal of Clinical Oncology. 40:3019-3019
3019 Background: Homologous recombination deficient (HRD) tumors are highly responsive to platinum-based chemotherapy and poly (ADP-ribose) polymerase inhibitor (PARPi) therapy. Pathogenic BRCA-1 and BRCA-2 (BRCA1/2) alterations are key members of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a7c6bed770a93662fb690d6b8fc7cfa
https://doi.org/10.1200/jco.2022.40.16_suppl.3019
https://doi.org/10.1200/jco.2022.40.16_suppl.3019
Autor:
Manuprasad Avaronnan, Rushabh Kothari, Avinash Talele, Vikas Talreja, Gautam Goyal, Nirmal Vivek Raut, Ashay Karpe
Publikováno v:
Journal of Clinical Oncology. 40:e21034-e21034
e21034 Background: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resulted in significant improvement in the outcomes of patients with activating EGFR mutations. But the ideal treatment of patients harboring uncommon, or compou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df959df39027663c96a60a4157c69e46
https://doi.org/10.1200/jco.2022.40.16_suppl.e21034
https://doi.org/10.1200/jco.2022.40.16_suppl.e21034
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 4, Iss 1, Pp 184-185 (2021)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::930910bf56508da99ab18ba183bcd4fa
http://www.crstonline.com/article.asp?issn=2590-3233
http://www.crstonline.com/article.asp?issn=2590-3233
Autor:
Nirmal Vivek Raut, Anant Ramaswamy, Ram Abhinav Kannan, K. Gupta, K Deepan Rajamanickam, Gautam Goyal, Ashay Karpe, Bhavesh Poladia, Bharatsinha Baburao Bhosale, Vipul Doshi, Joydeep Ghosh, Vikas Talreja, Arun Chandrasekharan, Avinash Talele, Manu Prasad, Rushab Kothari, Trinanjan Basu, Ashish Kumar Singh, Alok Goel
Publikováno v:
Journal of Clinical Oncology. 39:e21201-e21201
e21201 Background: Osimertinib is one of the favoured treatment options in EGFR mutated NSCLC and was established as a treatment option in last 2-3 years. However the treatment pattern post-osimertinib failure is not established. Hence we conducted t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d2ee386fd40f7eeefe0a7c9ca4c458b
https://doi.org/10.1200/jco.2021.39.15_suppl.e21201
https://doi.org/10.1200/jco.2021.39.15_suppl.e21201
Autor:
Aju Mathew, Nirmal Vivek Raut, Senthill J Rajappa, Vineet Talwar, Anurag Mehta, Raja Pramanik, Nitesh Rohatgi, Deepak Kumar Shukla, Serena Elizabeth Joseph, Vivek Agarwala, Bhawna Sirohi, Reetu Jain, Vinayak Maka
Publikováno v:
Journal of Clinical Oncology. 39:e18718-e18718
e18718 Background: Comprehensive genomic profiling (CGP) assay, a next-generation sequencing (NGS) based technique generates a large amount of genomic information about a cancer. While CGP is increasingly used in low-middle income countries (LMIC), l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cafae7aeeb8f4c12cd9af39271e3554e
https://doi.org/10.1200/jco.2021.39.15_suppl.e18718
https://doi.org/10.1200/jco.2021.39.15_suppl.e18718